Actively Recruiting
Safety and Efficacy of a Multi-branched Thoracoabdominal Stent Graft System for Thoracoabdominal Aortic Aneurysm.
Led by Lifetech Scientific (Shenzhen) Co., Ltd. · Updated on 2025-06-22
73
Participants Needed
1
Research Sites
372 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Evaluation of the safety and efficacy of a multi-branched thoracoabdominal stent graft system for thoracoabdominal aortic aneurysm.
CONDITIONS
Official Title
Safety and Efficacy of a Multi-branched Thoracoabdominal Stent Graft System for Thoracoabdominal Aortic Aneurysm.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years
- Diagnosed with thoracoabdominal aortic aneurysm based on specific guidelines
- Aneurysm maximum diameter greater than 50mm or increased size by more than 5mm in 6 months or 10mm in 1 year
- Proximal anchoring region diameter 17-36 mm and length at least 25 mm
- Distal anchoring region diameter 7-25 mm (iliac artery) or 12-36 mm (abdominal aorta) with minimum length
- Visceral branch vessel anchoring diameter 6-13 mm and length at least 15 mm
- Renal artery anchoring area diameter 4.5-9 mm and length at least 15 mm
- Suitable iliac, femoral, and upper limb artery access
- Able to understand trial purpose, consent voluntarily, and complete follow-up
You will not qualify if you...
- Hemodynamically unstable with ruptured thoracoabdominal aortic aneurysms
- Thoracoabdominal aortic dissection
- Mycotic or infectious thoracoabdominal aortic aneurysm
- Systemic or local infection increasing graft infection risk
- Occlusion of superior mesenteric, celiac, or renal artery
- Need for simultaneous coverage and embolization of both internal iliac arteries
- Severe stenosis, calcification, or thrombus in stent anchoring area
- Acute coronary syndrome within 6 months
- Transient ischemic attack or stroke within 3 months
- Significant liver or kidney function abnormalities
- Severe lung problems preventing general anesthesia
- Severe coagulation problems
- Major surgery or intervention within 30 days before procedure
- Allergy to contrast agents, anticoagulants, antiplatelet drugs, stents, or related materials
- Connective tissue diseases like lupus, Marfan's, Adam's, or Behcet's disease
- Takayasu arteritis
- Serious vital organ dysfunction or other serious diseases
- Pregnancy, planning pregnancy, or breastfeeding
- Participation in other clinical trials without withdrawal in first 3 months
- Life expectancy less than 1 year
- Investigator judgment of ineligibility for endotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
W
Wei Guo, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here